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Summary
Background The optimal invasive treatment for sciatica secondary to herniated lumbar disc remains controversial, 
with a paucity of evidence for use of non-surgical treatments such as transforaminal epidural steroid injection (TFESI) 
over surgical microdiscectomy. We aimed to investigate the clinical and cost-effectiveness of these options for 
management of radicular pain secondary to herniated lumbar disc.
Methods We did a pragmatic, multicentre, phase 3, open-label, randomised controlled trial at 11 spinal units across 
the UK. Eligible patients were aged 16–65 years, had MRI-confirmed non-emergency sciatica secondary to herniated 
lumbar disc with symptom duration between 6 weeks and 12 months, and had leg pain that was not responsive to 
non-invasive management. Participants were randomly assigned (1:1) to receive either TFESI or surgical 
microdiscectomy by an online randomisation system that was stratified by centre with random permuted blocks. The 
primary outcome was Oswestry Disability Questionnaire (ODQ) score at 18 weeks. All randomly assigned participants 
who completed a valid ODQ at baseline and at 18 weeks were included in the analysis. Safety analysis included all 
treated participants. Cost-effectiveness was estimated from the EuroQol-5D-5L, Hospital Episode Statistics, medication 
usage, and self-reported resource-use data. This trial was registered with ISRCTN, number ISRCTN04820368, and 
EudraCT, number 2014-002751-25.
Findings Between March 6, 2015, and Dec 21, 2017, 163 (15%) of 1055 screened patients were enrolled, with 
80 participants (49%) randomly assigned to the TFESI group and 83 participants (51%) to the surgery group. At 
week 18, ODQ scores were 30·02 (SD 24·38) for 63 assessed patients in the TFESI group and 22·30 (19·83) for 
61 assessed patients in the surgery group. Mean improvement was 24·52 points (18·89) for the TFESI group and 
26·74 points (21·35) for the surgery group, with an estimated treatment difference of –4·25 (95% CI –11·09 to 2·59; 
p=0·22). There were four serious adverse events in four participants associated with surgery, and none with TFESI. 
Compared with TFESI, surgery had an incremental cost-effectiveness ratio of £38 737 per quality-adjusted life-year 
gained, and a 0·17 probability of being cost-effective at a willingness-to-pay threshold of £20 000 per quality-adjusted 
life-year.
Interpretation For patients with sciatica secondary to herniated lumbar disc, with symptom duration of up to 
12 months, TFESI should be considered as a first invasive treatment option. Surgery is unlikely to be a cost-effective 
alternative to TFESI.
Funding Health Technology Assessment programme of the National Institute for Health Research (NIHR), UK.
Copyright © 2021 Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.
Introduction 
Herniated lumbar disc resulting in back and leg pain 
travelling below the knee, sciatica, or radiculopathy is a 
worldwide burden to society.1 The condition affects an 
estimated 11% of patients presenting to their primary-
care provider worldwide, with an annual prevalence 
estimated to be 2·2%.2,3 Generally, outcomes are 
favourable and 80% of patients improve with conservative 
care within 12–24 months.4 However, given that patients 
affected by this condition are typically aged 40–45 years, 
there is a risk of loss of livelihood if it is not managed 
promptly.2,3
Treatment options have been considered by various 
expert-led guidelines,5–7 but no consensus exists for 
transforaminal epidural steroid injection (TFESI) due 
to a scarcity of class I evidence. Generally, once analgesia 
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and lifestyle-modifying treatments have failed, steroid 
nerve root injections and surgical microdiscectomy are 
recommended for severe persistent cases. Stepwise care 
approaches based on treatment with non-opioids have 
been identified as likely to represent a more cost-effective 
approach than strategies involving direct referral for disc 
surgery;8 however, evidence for a stepwise treatment 
progression involving TFESI is scarce. Following various 
randomised trials comparing surgical treatments with 
non-surgical therapy,9–12 surgery is often deemed the most 
successful treatment option, leading to more than 
10 000 discectomy procedures per year in the UK and 
190 000 such procedures in the USA.13 The costs to the 
UK’s National Health Service (NHS) for microdiscectomy 
(requiring patients to be hospitalised for 2 nights, on 
average) are approximately £4500 com pared with £700 for 
TFESI.14
A single-centre randomised trial of 128 patients 
compared surgery with conservative care (including 
steroid injections) for sciatica secondary to herniated 
lumbar disc and found that surgery provided better 
clinical improvement in leg pain scores by 24 points.15 
Although this study reported a surgical benefit, there was 
a clear difference in safety profiles between treatments, 
with nine adverse events (including one nerve root injury) 
in patients receiving surgery and none in patients 
managed conservatively. Furthermore, a single-institution 
study might not be generalisable across wider health-care 
providers. Although treatment for radiculo pathy with 
TFESI offers theoretical cost advantages and reduced risk 
compared with surgery, robust class I clinical data 
supporting its efficacy are scarce,8,16 and there is no 
worldwide consensus on the use of TFESI.3 We are aware 
of only one other trial comparing the direct effect of 
surgery with that of epidural steroid injections in 
100 patients with sciatica secondary to lumbar disc 
herniation.17 However, this trial was also a single-centre 
study and the route of administration was via a posterior 
interlaminar (lumbar puncture) injection, as opposed to 
TFESI. The trial showed that steroid injections avoided 
the need for surgery in 23 (46%) of 50 patients.17 In view of 
conflicting clinical evidence, we aimed to complete the 
first multicentre, randomised controlled trial comparing 
the clinical effectiveness of TFESI with that of surgical 
microdiscectomy for management of radicular pain 
secondary to herniated lumbar disc in patients with 
non-emergency presentation of sciatica with symptom 
duration of up to 12 months. We also aimed to assess cost-




NERVES is a pragmatic, multicentre, phase 3, randomised 
controlled trial, with an internal pilot phase, comparing 
surgical microdiscectomy with TFESI in patients with 
sciatica secondary to herniated lumbar disc with symptom 
duration of up to 12 months. Participants were recruited 
from and followed up at 11 spinal tertiary units (outpatient 
neurosurgical, pain, and orthopaedic clinics; appendix 
pp 2–3) across the UK. The initial plan was to limit 
duration of symptoms at screening to 6 months. However, 
this criterion had a negative impact on recruitment 
because few patients were receiving specialist treatment 
within the NHS by this time, so the protocol was extended 
to 1 year of symptoms. The main aim of treatment was to 
relieve sciatica symptoms in patients as quickly and safely 
as possible.
An independent trial steering committee viewed reports 
with treatment assignment concealed, and an independent 
Research in context
Evidence before this study
There is considerable uncertainty about the clinical effectiveness 
of epidurals in sciatica compared with surgery for treatment of 
herniated lumbar disc. However, transforaminal epidural steroid 
injection (TFESI), a newer and more precise treatment option, 
offered promise given that it can deliver the drug in a closer 
proximity to the site of pathology. We searched PubMed using 
the term “sciatica epidural steroid” immediately before the 
initial development of the NERVES protocol in 2013–14 and 
found that previous evidence supporting TFESI had come from 
cohort studies or single-centre studies, without clear 
specification of the non-surgical treatments provided. A meta-
analysis from 2015 suggested that non-opioid analgesia, TFESI, 
and surgery were effective management options for sciatica 
secondary to uncomplicated herniated lumbar disc. However, 
the effectiveness of TFESI compared with surgery for herniated 
lumbar disc was uncertain, leading to wide variation in 
management guidelines for this common condition.
Added value of this study
NERVES is the first multicentre randomised trial directly 
comparing surgical microdiscectomy with TFESI on a 
1:1 allocation basis as initial invasive treatment for sciatica 
secondary to herniated lumbar disc. There was no significant 
difference between TFESI and surgery pathways in clinical 
outcome, and surgery is unlikely to be a cost-effective 
alternative to TFESI. Complications of surgery were significant, 
offsetting any benefits of surgery as an early treatment, 
whereas only minor adverse events were seen with TFESI.
Implications of all the available evidence
NERVES provides high-quality evidence for a stepwise 
treatment framework of uncomplicated sciatica secondary to 
herniated lumbar disc with symptom duration of up to 
12 months. TFESI would be less costly as an initial alternative to 
surgery for this condition, while achieving similar levels of 
improved outcomes.
See Online for appendix
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data monitoring committee viewed unmasked reports 
regularly to assess conduct and progress, including safety. 
The trial was granted Clinical Trial Authorisation 
(reference 21322/004/001) by the Medicines and Healthcare 
products Regulatory Agency. The trial protocol was also 
approved by a research ethics committee (National 
Research Ethics Service Committee North West–Liverpool 
Central; reference 14/NW/1219) and has been published.18
Participants 
All participants required an MRI diagnosis of nerve 
compression secondary to herniated lumbar disc and had 
leg pain that was non-responsive to at least one attempt of 
conservative, non-invasive management. A screening log 
was maintained at each trial centre, with information on 
eligibility, consent, and randomisation. Eligible partici-
pants were aged 16–65 years, had clinical evaluation of leg 
pain by a consultant spinal surgeon that was deemed 
concordant with nerve compression seen on MRI, and 
had a duration of symptoms between 6 weeks and 
12 months. Patients with emergency cases of significant 
ankle weakness or threatened cauda equina syndrome 
were excluded, as were those with far lateral disc prolapses. 
A full list of inclusion and exclusion criteria is in the 
appendix (p 2). Eligible participants provided written 
informed consent before participating in the trial.
Randomisation and masking 
Participants were randomly assigned (1:1) to receive either 
TFESI or surgical microdiscectomy (surgery) with an 
online randomisation system. A designated member of 
the site team, usually a clinician or nurse involved in the 
participant’s care, did the online randomisation. 
Randomisation was stratified by centre and used permuted 
blocks of random variable length (block sizes two and 
four). The randomisation sequence was generated by an 
inde pendent statistician, and allocations were concealed 
from investigators and participants before recruitment. It 
was not possible to mask investigators and participants 
due to the treatments received.
Procedures 
Surgery for posterolateral herniated lumbar disc was done 
following a standard open surgical microdiscectomy 
technique with an operative microscope, delivered by a 
consultant spinal surgeon. Specialists identified the 
correct side and level before treatment with level 
localisation using an image intensifier. The nature of disc 
prolapse (eg, contained, extruded, or sequestrated) was 
recorded by the operating surgeon, along with spinal level.
TFESI was completed by pain specialists, radiologists, 
or spinal surgeons as per local policy or technique with 
the lateral foraminal portal of entry. All fluoroscopically 
guided techniques were permitted to specify the correct 
level. Radiological level and appropriate spread of 
contrast were confirmed by the operator. To minimise 
variability across participating centres, the recommended 
injection regimen was 20–60 mg triamcinolone 
acetonide and 2 mL of 0·25% levobupivacaine. A second 
injection of the same dose was permitted if the injection 
was considered partially effective.
For both groups, treatment was recommended within 
6 weeks of randomisation. Participants were allowed to 
crossover and subsequently receive the non-allocated 
treatment if primary treatment was considered ineffective. 
Participants were followed up for 54–62 weeks. 
Questionnaires were collected at 18, 30, 42, and 54 weeks, 
each within a window of 2 weeks. All questionnaires were 
completed at hospital visits, except for those at 30 and 
42 weeks, which were delivered by post. The types of data 
and collection methods are detailed in the study protocol.18
An assessment of related adverse events was done at 
each study clinic visit at 18 weeks and 54 weeks after 
treatment. All related serious adverse events were 
reported within 24 h of site awareness of event. Related 
adverse events and serious adverse events were reported 
throughout the trial follow-up period.
Outcomes 
The primary outcome was patient-reported Oswestry 
Disability Questionnaire (ODQ) score (range 0–100) at 
18 weeks after randomisation.19 Secondary outcomes were 
ODQ score at weeks 30, 42, and 54;19 numerical rating 
scores (range 0–100) for leg pain and back pain, two-item 
Likert Scale (range 1–5) to assess patient treatment 
satisfac tion,20 Modified Roland-Morris (MRM) outcome 
score (range 0–24) for sciatica,21 and Core Outcome 
Measures Index (COMI) score (range 0–10)20 at weeks 18, 
30, 42, and 54; work status (eg, return to work and work 
days lost, if applicable); and cost-effectiveness, expressed 
as incremental cost per quality-adjusted life-year (QALY) 
gained, assessed with EuroQol 5D-5L. 
Statistical analysis 
To detect a clinically important difference of 10 points on 
the ODQ at a 5% significance level with 90% power, a total 
of 172 participants were required. The choice of 10 points 
is based on widely accepted practice, and is at the lower 
end of the range of differences recommended in a study 
specifically addressing the issue.22 We assumed an SD of 
20 points on the basis of a similar population in UK-based 
trials.23 The initial target sample size for the trial was 200, 
which would allow for a 10% rate of missing outcome 
data. Because this initial sample size calculation did not 
account for the analysis being adjusted for baseline values 
of ODQ, and because recruitment targets were not being 
met, the sample size was recalculated after outcome data 
was received for 47 participants. A masked analysis of 
correlation between baseline and follow-up ODQ scores 
was done to adjust the sample size calculation. Based on 
the observed correlation of 0·49, the revised sample size 
to achieve 90% power was 66 participants per group, 
which was increased to 74 participants per group (148 in 
total) to allow for 10% loss to follow-up.
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Analyses followed a prespecified statistical analysis 
plan. The primary outcome (ODQ score at 18 weeks after 
randomisation) was compared between groups with a 
linear regression model, adjusted for baseline ODQ, 
with centre as a random effect. ODQ score, visual 
analogue scores (VAS) for back pain, VAS for leg pain, 
MRM outcome score, and COMI score at all follow-up 
visits were analysed with a repeated measures mixed-
effects model adjusting for baseline outcome measure, 
treatment group, time (as a continuous variable), and a 
time-treatment arm interaction (if significant). Centre 
and participant were random effects in the repeated 
measures models. A second model adjusted for other 
prespecified variables, age, sex, duration of symptoms, 
body-mass index, and size of disc prolapse (as a 
percentage of the diameter of the spinal canal, categorised 
as <25%, 25–50%, or >50%). The Likert scale for 
satisfaction with care was analysed with the Mann-
Whitney U test. Employment status was analysed with a 
χ² test. The intention-to-treat principle was applied as far 
as was possible (ie, where data were available). The 
analysis set for the primary outcome included all 
participants with a valid ODQ score (≥8 of 10 items) at 
baseline and at 18 weeks (range 12–24 weeks) after 
randomisation. The safety analysis was done in all 
participants who were treated and received at least one 
surgery or TFESI.
A sensitivity analysis was done with multiple 
imputation to assess the robustness of the analysis to 
missing primary outcome data (appendix pp 36–37).
A post-hoc analysis was done with joint modelling of 
the longitudinal outcomes (ie, ODQ scores, VAS back 
pain, VAS leg pain, MRM scores, and COMI scores) and 
the time to study dropout for each outcome to address 
the possibility of informative dropout (appendix p 37).
All analyses were done using SAS Software (version 9.4), 
with the exception of the joint modelling analyses, which 
used the joineR package in R.24
Economic analysis 
The economic analysis was done over the 54 week trial 
period and adopted the perspective of the NHS in 
England, UK (appendix pp 12–33). Within-trial resource 
use was obtained from routine NHS Hospital Episode 
Statistics patient-level data, trial case report forms, and 
patient-completed questionnaires. Patient questionnaires 
were administered at baseline and treatment visits, and 
at approximately weeks 18, 30, 42, and 54 after baseline. 
Unit costs were obtained from standard sources,14,25,26 
valued in sterling, and based on 2017–18 prices with 
inflation indices applied as necessary (appendix pp 12–17). 
Utilities were estimated from responses to the EuroQol 
5D-5L multi-attribute utility instrument and applying the 
3L mapping algorithm.27 Treatment costs were applied on 
the basis of treatment received.
When data were missing for utilities at baseline, 
weeks 18 or 54, or for any patient-completed resource use 
cost data, completed datasets were generated via multiple 
imputation before analysis. QALYs were modelled using 
linear regression, and total costs using a generalised 
linear model with a log-link function and gamma 
probability distribution. The QALY model included 
covariates for treatment allocation and baseline utility, 
and the model for total costs included covariates for 
treatment allocation and baseline costs.
The primary outcome of the economic evaluation was 
the incremental cost per QALY of surgery compared with 
that of TFESI. Uncertainties in economic outcomes were 
analysed using non-parametric bootstrapping, with 
Figure 1: Trial profile
TFESI=transforaminal epidural steroid injection.
80 allocated to TFESI group
 70 received allocated 
  intervention
 3 received surgery 
 7 received neither intervention 
1055 individuals assessed for eligibility
163 randomly assigned
83 allocated to surgery group
 71 received allocated 
intervention
 5 received TFESI 
 7 received neither intervention  
5 lost to follow-up
3 withdrew from trial
4 lost to follow-up
3 withdrew from trial
Allocation
18 weeks
3 lost to follow-up4 lost to follow-up 
30 weeks
3 lost to follow-up 3 lost to follow-up
42 weeks
7 lost to follow-up 5 lost to follow-up
54 weeks
63 included in primary outcome 
analysis 
17 excluded from analysis
 3 did not complete 
  questionnaire within 
  12–24 weeks of 
  randomisation
 14 had missing data 
61 included in primary outcome 
analysis
22 excluded from analysis 
 7 did not complete 
  questionnaire within 
  12–24 weeks after 
  randomisation
 15 had invalid or missing data 
Analysis
892 excluded 
 723 did not meet inclusion 
criteria
 24 not approached for 
consent
 143 declined to participate
 1 had approach or 
consent data missing
 1 had eligibility data 
  missing 
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10 000 replications of the patient-level data, and presented 
as probabilities of cost-effectiveness at threshold levels of 
willingness to pay. Methods for the base-case analysis are 
presented in the appendix (pp 20–21). Scenario analyses 
comprised inclusion of participants with complete 
datasets only, out-of-pocket costs and productivity losses 
arising from time off work that approximated a societal 
perspective, alternative QALY valuation methods, the 
effect of varying the doses of as-needed medications, and 
considering only sciatica-related costs.
This trial was registered with ISRCTN, number 
ISRCTN04820368, and EudraCT, number 2014-002751-25.
Role of the funding source 
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results 
Between March 6, 2015, and Dec 21, 2017, we assessed 
1055 patients for eligibility and recruited 163 participants 
from 11 centres (figure 1, table 1). The trial stopped when 
all participants had completed follow-up. 80 participants 
(49%) were randomly assigned to the TFESI group and 
83 participants (51%) to the surgery group (figure 1; 
appendix pp 2–5). Mean length of symptom duration at 
time of treatment for patients who received treatment 
during the trial was 26·8 weeks. The majority of prolapses 
(92 [56%] of 163) occurred at L5–S1. Most operated cases 
(53 [72%] of 74) were for contained disc prolapses. Almost 
all cases (98 [93%] of 105) were operated directly by 
consultant spinal surgeons, with the remainder being 
done by senior trainees under direct consultant super-
vision.
Some participants did not receive the allocated treatment. 
Of the 83 patients randomly assigned to the surgery group, 
seven (8%) received TFESI only and four (5%) received 
neither treatment during the trial (appendix p 6). Of the 
80 patients randomly assigned to the TFESI group, 
five (6%) received surgery only and four (5%) received 
neither treatment (appendix p 6).
During the trial, 28 patients (35%) allocated to the TFESI 
group received both trial treatments, and four patients 
(5%) allocated to the surgery group received both 
interventions (appendix p 6). Seven patients overall (4%; 
two in the TFESI group and five in the surgery 
group) received a second TFESI injection during the study, 
at times ranging from the same day as the first injection to 
235 days later.
63 (79%) of 80 patients randomly assigned to the TFESI 
group and 61 (73%) of 83 patients in the surgery group 
were included in the primary outcome analysis. Both 
groups showed similar improvements in ODQ scores 
from baseline to week 18 (table 2). A post-hoc classification 
showed that a similar proportion of participants in both 
groups achieved an improvement of 10 points or more on 
the ODQ. Only eight participants (13%) in the surgery 
group and six (10%) in the TFESI group showed deterior-
ation in symptoms.
ODQ scores did not differ between groups at week 18, 
with the model effect estimate of surgery versus TFESI 
being –4·25 (95% CI –11·09 to 2·59; p=0·22). From this 
model, we estimate that surgery would result in an average 
improvement in ODQ score of 4·25 points more than 
would TFESI, which is less than the minimum clinically 
important difference of 10 points. Figure 2 presents the 
distribution of ODQ score improvements at the primary 
outcome timepoint of 18 weeks after randomisation.
Of the 61 patients randomly assigned to the surgery 
group and who were included in the primary analysis, 
two (3%) also received TFESI before completing the 
questionnaire at week 18. In the TFESI group, 13 (21%) 
of 63 participants with valid primary outcome data 
received surgery after receiving TFESI.
The second model, adjusting for additional covariates, 
gave an effect estimate of surgery versus TFESI of –5·03 
(–12·76 to 2·70). An additional variable, level of disc 
prolapse, was included in a post-hoc analysis. This model 
resulted in an estimate of –4·94 (–12·81 to 2·93).
Because more than 10% of data was missing (39 [24%] of 
163 participants) for the primary outcome, a sensitivity 
analysis was done using multiple imputation. The effect 
estimate of surgery versus TFESI from the imputation 
analysis was –3·08 (–10·16 to 3·99). A post-hoc sensitivity 
analysis was done using multiple imputation, but only 
using baseline ODQ to impute a score for week 18. The 
effect estimate of surgery versus TFESI from the post-hoc 
imputation analysis was –3·26 (–9·91 to 3·39). The 
assumption of missing at random was explored with 
pattern mixture modelling and did not change conclusions. 
Additional details on the imputation are in the 
appendix (pp 36–37).
ODQ scores at week 18 in the longitudinal model 
improved by 27·2 points in the surgery group, compared 
Surgery group (n=83) TFESI group (n=80)
Sex
Female 46 (55%) 40 (50%)
Male 37 (45%) 40 (50%)
Age, years 43·5 (9·9) 41·2 (8·6)
Body-mass index, kg/m² 28·2 (5·3)* 27·2 (6·4)†
Weeks with symptoms 21·5 (10·7) 21·1 (11·2)
Currently employed‡
No 21 (25%) 13 (16%)
Yes 62 (75%) 66 (84%)
Not able to work 41 (66%) 34 (52%)
Able to work 21 (34%) 32 (48%)
Data are n (%) or mean (SD). TFESI=transforaminal epidural steroid injection. 
*Data available for 74 participants. †Data available for 68 participants. ‡Data 
available for 83 patients in the surgery group and 79 participants in the TFESI 
group. 
Table 1: Baseline characteristics
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with 24·3 points in the TFESI group (appendix pp 10–11). 
The adjusted estimate for the average effect of 
surgery versus TFESI over all timepoints was 
–4·67 (–10·61 to 1·28; p=0·12). For the joint modelling 
post-hoc analysis of ODQ scores, the adjusted effect 
estimate of surgery versus TFESI was –4·62 (–9·84 to 1·27; 
p=0·11; appendix p 37).
Leg pain VAS scores at week 18 improved by 58·3 points 
in the surgery group, compared with 43·6 points in the 
TFESI group (appendix pp 10–11). The adjusted estimate 
for the average effect of surgery versus TFESI over all 
timepoints was –7·04 (–15·81 to 1·73; p=0·11). For the 
joint modelling post-hoc analysis of VAS leg pain scores, 
the adjusted effect estimate of surgery versus TFESI 
was –7·06 (–15·82 to 0·86; p=0·098; appendix p 37).
Back pain VAS scores at week 18 improved by 
26·0 points in the surgery group, compared with 
23·4 points in the TFESI group (appendix pp 10–11). 
The adjusted effect estimate of surgery versus TFESI 
was –3·01 (–11·29 to 5·26; p=0·47). For the joint 
modelling post-hoc analysis of VAS back pain scores, the 
adjusted effect estimate of surgery versus TFESI 
was –2·87 (–10·58 to 3·16; p=0·46; appendix p 37).
MRM scores at week 18 improved by 9·1 points in the 
surgery group, compared with 7·7 points in the TFESI 
group (appendix pp 10–11). The adjusted effect estimate 
of surgery versus TFESI was –1·82 (–3·67 to 0·03; 
p=0·054). For the joint modelling post-hoc analysis of 
MRM scores, the adjusted effect estimate of surgery 
versus TFESI was –1·72 (–3·44 to 0·10; p=0·063; 
appendix p 37).
COMI scores at week 18 improved by 3·9 points in the 
surgery group, compared with 3·1 points in the TFESI 
group (appendix pp 10–11). The adjusted effect estimate 
of surgery versus TFESI was –0·77 (–1·58 to 0·03; 
p=0·059). For the joint modelling post-hoc analysis of 
COMI scores, the adjusted effect estimate of surgery 
versus TFESI was –0·78 (–1·54 to –0·02; p=0·046; 
appendix p 37). The estimate for surgery versus TFESI is 
similar to the longitudinal mixed model; however, 
95% CIs suggest a significant treatment effect once 
adjusted for informative dropout, although this is less 
than the minimal clinically important difference of 2·2.28
No participants died during the study period. There 
were 26 adverse events, 18 events in 15 participants who 
had surgery and eight events in three participants who 
had TFESI (table 3). There were four serious adverse 
events in four participants, all associated with surgery 
(appendix pp 34–35). None of the serious adverse events 
were unexpected. One (1%) of the 105 participants who 
ended up having surgery developed a clinically significant 
nerve palsy (ie, foot drop).
Data for 157 participants were included in the economic 
evaluation (80 in the surgery group and 77 in the TFESI 
group). Six participants who withdrew early on were 
excluded because neither outcome nor Hospital Episode 
Statistics data were available. Some data were missing for 
costs and EuroQol 5D-5L, in particular the postal 
questionnaires at weeks 30 and 42 (appendix p 22). 
Observed participants’ use of health-care resources were 
similar at baseline for the 3 months before randomisation 
(appendix pp 23–24). Observed use of resources in primary 
and secondary care during the 54 week trial period are 
reported in the appendix (pp 24–25). The corresponding 
NHS costs were higher for surgery at £6683 (95% CI 
£5632–8074) than for TFESI at £4422 (£3682–5291), with a 
difference of £2261 (£706–3589; table 4; appendix pp 25–26), 
mainly due to cost differences in admitted patient care.
Utility scores were similar between groups at baseline 
(appendix p 27). At 54 weeks, mean observed utility 
was 0·718 (0·649 to 0·784) for the surgery group and 0·659 
(0·573 to 0·739) for the TFESI group. There was no 
evidence of a significant difference in QALYs over the 
54 week trial duration (difference 0·062 [–0·033 to 0·155]; 
table 4; appendix pp 27–28).
The base-case analysis with imputation for missing data, 
regression analysis, and non-parametric boot strapping 
Figure 2: Distribution of differences in ODQ scores between baseline and 
week 18
Fitted lines are kernel density estimates; histogram show percentage of patients 
in nine bins. TFESI=transforaminal epidural steroid injection. ODQ=Oswestry 
Disability Questionnaire.






















Difference in ODQ score
TFESI group
Surgery group
Surgery group TFESI group Total
ODQ score at baseline* 49·39 (17·81) 53·74 (19·35) 51·51 (18·64)
ODQ score at week 18† 22·30 (19·83) 30·02 (24·38) 26·22 (22·51)
Difference in ODQ scores 
(SD; 95% CI)†
–26·74  
(21·35; –32·21 to –21·27)
–24·52  
(18·89; –29·28 to –19·76)
–25·61  
(20·09; –29·18 to –22·04)
Difference category (post-hoc)
≥10 point improvement 45 (74%) 43 (68%) 88 (71%)
<10 point improvement 8 (13%) 14 (22%) 22 (18%)
Deterioration in 
symptoms
8 (13%) 6 (10%) 14 (11%)
Data are mean (SD) or n (%), unless otherwise indicated. TFESI=transforaminal epidural steroid injection. ODQ=Oswestry 
Disability Questionnaire. *Data available for 83 participants in the surgery group and 79 participants in the TFESI group. 
†Data available for 61 participants in the surgery group and 63 participants in the TFESI group.  
Table 2: Summary of ODQ scores at baseline and at week 18
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yielded total costs of £6919 (£5503 to £8046) and total 
QALYs of 0·616 (0·570 to 0·671) for surgery, and total costs 
of £4706 (£3821 to £5516) and total QALYs of 0·559 
(0·503 to 0·620) for TFESI. Incremental costs of £2212 
(£629 to £3677) and QALYs of 0·057 (–0·009 to 0·124) 
resulted in an incremental cost-effectiveness ratio of 
£38 737 per QALY gained and a 0·17 probability of surgery 
being cost-effective at a willingness-to-pay threshold 
of £20 000 per QALY (table 4; appendix pp 28–29).
None of the scenario analyses that used imputed 
datasets resulted in incremental cost-effectiveness 
ratios below the £20 000 per QALY gained threshold 
(appendix p 31).
Discussion 
To our knowledge, NERVES is the first randomised trial to 
directly compare surgical microdiscectomy with TFESI as 
initial invasive treatments for management of radicular 
pain secondary to herniated lumbar disc in patients with 
non-emergency presentation of sciatica with symptom 
duration of up to 12 months. No significant differences 
were found for primary or secondary outcomes, with 
47 (59%) of the 80 patients in the TFESI group not 
receiving surgery. This study was a pragmatic trial done 
within the NHS, recruiting patients whose symptoms had 
not improved within 6 weeks of conser vative management 
and required additional treatment. Given the National 
Institute for Health and Care Excellence (NICE) cost-
effectiveness threshold of £20 000 per QALY, and that our 
results reported an incremental cost-effectiveness ratio 
of £38 737 per QALY gained, it is unlikely that surgery as a 
first invasive treatment would be considered a cost-
effective use of NHS resources, compared with TFESI. 
Our findings were robust to several modelling scenarios 
and assumptions, and indicated that incremental QALY 
gains did not justify the increased costs of surgery.
Previous studies of sciatica comparing surgery with 
conservative management have reported surgery to be 
more effective than non-operative management. A 
2020 study with a similar cohort to NERVES showed that 
surgery was superior to non-operative management in 
patients with sciatica of up to 12 months duration, with leg 
pain improvements greater than 20 points following 
surgery.15 The primary outcome of the study was leg pain; 
however, because the trial was limited to one health-care 
institution, it might not be generalisable across wider 
populations. Although we found that surgery resulted in 
greater improvements in leg pain than did TFESI, this 
effect was limited to 7 of 100 VAS points.
The NERVES trial has methodological strengths: it was 
multicentred (11 units) across a single country and the 
treatment policy for the non-surgical group was clearly 













Total 18 15 (14%) 8 3 (4%) 26 18 (12%)
Nervous system disorders
Hypoaesthesia 1 1 (1%) 5 2 (2%) 6 3 (2%)
Cerebrospinal fluid leakage 1 1 (1%) 0 0 (0%) 1 1 (1%)
Peroneal nerve palsy 1 1 (1%) 0 0 (0%) 1 1 (1%)
Radicular pain 1 1 (1%) 0 0 (0%) 1 1 (1%)
Injury, poisoning, and procedural  complications
Dural tear 4 4 (4%) 0 0 (0%) 4 4 (3%)
Pseudomeningocele 2 2 (2%) 0 0 (0%) 2 2 (1%)
Surgical procedure repeated 1 1 (1%) 0 0 (0%) 1 1 (1%)
Wound complication 1 1 (1%) 0 0 (0%) 1 1 (1%)
Infections and infestations
Post-operative wound infection 2 2 (2%) 0 0 (0%) 2 2 (1%)
Wound infection 1 1 (1%) 0 0 (0%) 1 1 (1%)
Musculoskeletal and connective tissue disorders
Pain in extremity* 1 1 (1%) 1 1 (1%) 2 2 (1%)
Sciatica 1 1 (1%) 0 0 (0%) 1 1 (1%)
Renal and urinary disorders
Pollakiuria 0 0 1 1 (1%) 1 1 (1%)
Urinary incontinence 0 0 1 1 (1%) 1 1 (1%)
General disorders and administration site conditions
Swelling 1 1 (1%) 0 0 (0%) 1 1 (1%)
Adverse events are reported by treatment received rather than by allocated treatment. TFESI=transforaminal epidural steroid injection. *Refers to leg pain.
Table 3: Adverse events
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defined (ie, TFESI). Additionally, the chosen outcome 
instruments conformed to a recently defined core outcome 
dataset for low back pain.29 Further more, as well as pain 
scores, functional assessments included ODQ and MRM 
(a sciatica-specific outcome), and an economic evaluation 
was included. The economic analysis has strengths in the 
use of routine patient-level NHS datasets and nationally 
reported costs, collected within a pragmatic, randomised 
controlled trial designed to reflect current management 
and NHS practice. Participant-reported health outcomes 
were reported using the EuroQol-5D-3L mapping 
algorithm, which is preferred by NICE. Deriving 
EuroQol-5D scores from the ODQ, this trial’s primary 
outcome measure, was deemed unfeasible because no 
robust relationship exists between these measures.30
Limitations of the study include a degree of missing data 
and treatment crossover. It is possible that a difference of 
10 points on the ODQ between the two treatments has 
been missed, given the 95% CIs found. However, the 
improvements in ODQ pain scores for the TFESI group 
were clinically significant in 43 (68%) of the 63 patients 
with complete and valid outcome data, and 47 (59%) of the 
80 patients in the TFESI group did not have surgery during 
the trial. The effect of missing data was addressed with 
sensitivity analyses and the primary results were found to 
be robust. Regarding treatment crossover, previous studies 
have reported crossover rates of between 30% and 60% for 
non-surgical treatment groups. In this trial, only 
13 (21%) of 63 patients in the TFESI group received surgery 
after they received TFESI and before the primary outcome 
assessment, which minimises primary outcome bias 
following intention-to-treat analysis. However, in total, 
33 (41%) of the 80 patients in the TFESI group received 
surgery: 28 (35%) after receiving TFESI first, five (6%) 
received surgery only, and a further four (5%) received no 
treatment at all during the study period. Given that costs 
accrued were based on treatments received, this introduces 
potential implications for the cost-effectiveness estimates 
that would be observed in real-world practice.
The economic analysis had limitations, especially in 
relation to missing data for the postal questionnaires. 
Where possible, we employed assumptions around 
resource use, costs, and quality of life to maximise 
the use of acquired data; however, where this was 
not possible, we relied on multiple imputation.31 Our 
estimation of productivity losses was included in a 
secondary analysis to reflect the high impact of sciatica on 
working days lost, but was subject to missing data 
and incomplete questionnaire reporting. Given that 
65% recurrence rates of lower back pain after discectomy 
at 3 years have been reported,32 applying a longer analytical 
time horizon might have provided insights into the 
longer-term estimate of cost-effectiveness. However, a 
modelled extrapolation would be liable to bias because 
participants of the NERVES trial were not followed up 
beyond 54 weeks.
Previous economic evaluations were found not to be 
generalisable to this analysis due to differences in setting, 
perspective, and interventions tested. A comparison 
between lumbar epidural steroid injection and placebo 
reported an incremental cost-effectiveness ratio 
of £44 701 per QALY gained (provider perspective, which 
most closely reflects the NHS).23 By contrast, NERVES 
used the preferable transforaminal route because the 
Surgery group TFESI group Mean difference
Observed costs, £*
Total National Health Service 6683 (5632 to 8074) 4422 (3682 to 5291) 2261 (706 to 3589)
Admitted patient care 5168 (4271 to 6475) 3242 (2617 to 3924) 1926 (467 to 3128)
Outpatient 1186 (1045 to 1327) 949 (842 to 1066) 237 (50 to 414)
Concomitant medications 262 (168 to 385) 183 (125 to 252) 78 (–62 to 199)
General practitioner 93 (52 to 137) 103 (56 to 166) –10 (–77 to 62)
Physiotherapy 38 (3 to 88) 18 (0 to 44) 19 (–35 to 62)
Emergency department 50 (10 to 100) 71 (26 to 128) –20 (–94 to 50)
Observed health outcomes, EuroQol -5D-3L value set†
Baseline utility 0·328 (0·259 to 0·392) 0·276 (0·188 to 0·366) 0·052 (–0·060 to 0·157)
54 week utility 0·718 (0·649 to 0·784) 0·659 (0·573 to 0·739) 0·059 (–0·051 to 0·165)
QALYs over 54 weeks 0·654 (0·588 to 0·709) 0·591 (0·518 to 0·658) 0·062 (–0·033 to 0·155)
Economic evaluation‡
Costs 6919 (5503 to 8046) 4706 (3821 to 5516) 2212 (629 to 3677)
QALYs 0·616 (0·570 to 0·671) 0·559 (0·503 to 0·620) 0·057 (–0·009 to 0·124)
Incremental cost-effectiveness ratio ·· ·· 38 737
Data are mean (95% CI). TFESI=transforaminal epidural steroid injection. QALY=quality-adjusted life-year. *Admitted patient care, outpatient, and concomitant medications 
data considered complete. General practitioner, physiotherapy, and emergency department visits (patient-reported) subject to missing data. †Health outcomes for 
participants with observations at baseline and at weeks 18 and 54, adjusted for visit time deviations (n=55 for surgery group and n=48 for TFESI group). ‡Following 
imputation, regression analysis, and non-parametric bootstrapping.
Table 4: Observed costs (£), health outcomes, and cost-effectiveness analysis results
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injectate is much nearer to the site of pathology, the 
prolapsed disc, and involved nerve root.
The safety profiles of both treatments were different. 
Four patients in the surgery group required prolonged 
hospitalisation, revision surgery, or repair of meningo-
coele. One (1%) of the 105 patients who had surgery 
suffered a complete foot drop, despite a negative 
exploratory procedure within the first 24 h (no obvious 
cause for the nerve dysfunction could be identified). By 
contrast, no patients in the TFESI group suffered any 
serious adverse events.
For the first time, NERVES reports that use of TFESI as 
the initial invasive treatment is similarly effective to 
surgical microdiscectomy at reducing pain and disability 
from sciatica with symptom duration between 6 weeks 
and 12 months. Given the safety of TFESI, along with the 
unlikely cost-effectiveness of surgery as a first invasive 
treatment, we recommend that treating physicians 
strongly consider the use of TFESI as a stepwise invasive 
treatment for sciatica without neurological deficit of 
up to 12 months’ duration. Surgery is still likely to be 
required for a considerable number of patients for whom 
TFESI might not be as effective. 
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